Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EXALGO

« Back to Dashboard
Exalgo is a drug marketed by Mallinckrodt Inc and is included in one NDA. It is available from five suppliers.

The generic ingredient in EXALGO is hydromorphone hydrochloride. There are thirteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

Summary for Tradename: EXALGO

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list17

Pharmacology for Tradename: EXALGO

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Clinical Trials for: EXALGO

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
Status: Completed Condition: Neuropathic Pain

Methadone and Hydromorphone For Spinal Surgery
Status: Recruiting Condition: Hydromorphone Use; Acute Postoperative Pain; Patient Satisfaction; Chronic Persistent Surgical Pain

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain
Status: Completed Condition: Postoperative Pain

Association Between Body Size and Response to Hydromorphone in ED
Status: Recruiting Condition: Pain

Fixed Dose of Intravenous Hydromorphone in the Treatment of Acute Pain
Status: Completed Condition: Acute Pain

Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study
Status: Not yet recruiting Condition: Healthy; Human; Adult; Parturient

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol
Status: Terminated Condition: Pain; Respiratory Depression

Single-arm Study to Assess the Safety of Hydromorphone HCl by Intrathecal Administration
Status: Recruiting Condition: Chronic Pain

Intrathecal Hydromorphone for Pain Control After Cesarean Section
Status: Recruiting Condition: Pain; Cesarean Section

Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump
Status: Recruiting Condition: Management of Chronic Pain

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-001Mar 1, 2010RXNo<disabled><disabled>
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-004Aug 24, 2012RXYes<disabled><disabled>
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-002Mar 1, 2010RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EXALGO

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-001Mar 1, 20105,702,725<disabled>
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-004Aug 24, 20125,914,131<disabled>
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-004Aug 24, 20125,702,725<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc